We evaluated T-cell mediated lymphokine activated killer (LAK) function during the late (greater than 5 months) reconstitution phase after T cell-depleted allogeneic bone marrow transplantation (BMT) for hematologic malignancy. Since LAK cells are sustained by interleukin-2 (IL-2). we also investigated the ability of post-BMT T cells to produce IL-2. These functions were investigated at the clonal level. More than 200 T-cell clones from six long-term BMT recipients were generated and compared with 60 T-cell clones derived from two normal controls. Almost all the CD8+ clonal cultures from BMT recipients expressed cytolytic activity in a lectin-dependent cellular cytoxicity H E IMMUNE reconstitution phase that follows alloge-T neic bone marrow transplantation (BMT) is associated with a persistent deficiency of cellular and humoral immune responses.' This results in increased susceptibility to infection* and may also determine a defective control of residual leukemic cells that survive the pretransplant conditioning therapy leading to leukemia relapse. ' A wave of CD3 -cells with granular lymphocyte morphology that are capable of mediating natural killer (NK) and lymphokine-activated killer (LAK) functions has been demonstrated as early as 3 weeks p~st-grafting.~.~ In addition, CD3 -clones with anti-leukemia activity have been generated from BMT patienk6 It has, therefore, been suggested that CD3-cytotoxic cells may control the occurrence of leukemia relapses after BMT. However, the anti-tumor cytotoxicity mediated by T-cell-derived LAK effectors has not been investigated in BMT recipients. T cells are detected in sizeable proportions 2 to 3 months after BMT, but abnormal T-cell phenotypes and functions persist for a prolonged period of time. T-cell abnormalities comprise inverted CD4/CD8 ratios and defects in the proliferative response to mitogens or alloantigens, helper function for B-cell differentiation, cytotoxic T-lymphocyte (CTL) response, and low interleukin-2 (IL-2) prod~ction.~.'~ We have recently reported that, after T-cell-depleted allogeneic BMT for hematologic malignancy, there is a predominance of T cells co-expressing NK-related antigens, such as CD57 (Leu 7) and CD1 lb, within both the T-helper and the T-cytotoxic cell subsets.16
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In normal blood, the vast majority of cytotoxic cell precursors display a CD8 + phenotype.17 Among CD8 + cells, only those lymphocytes expressing CD57 and CD1 l b respond to IL-2 by acquiring nonspecific cytotoxic (LAK) functions against tumor targets." In view of the aforementioned putative role of CD3 -cytotoxic cells for the control of leukemia relapse after BMT,5,6 we have investigated the cytotoxic function and the production of IL-2 by T cells from six BMT recipients in which co-expression of CD57 and CD11 b on the circulating CD8 + T cells was increased to -100%. Mononuclear cell samples were cloned in a high efficiency T-cell cloning system, and the cytolytic functions of more than 200 T-cell clones were subsequently determined. Almost all of the CD8+ clonal cultures from all patients expressed cytolytic activity in a lectin-dependent cellular cytotoxicity (LDCC) assay. Interestingly, a higher proportion of these clones, as compared with control clones, was able to mediate LAK functions. A low production of IL-2 was consistently observed for BMT recipient-derived clones. This suggests that, in spite of the high frequency of LAK precursors with a T-cell phenotype, the cytotoxic function of these cells may be defective in vivo.
MATERIALS AND METHODS
Twenty subjects undergoing BMT for hematologic malignancy (14 with acute leukemia, 4 with chronic myelogenous leukemia, 1 with non-Hodgkin's lymphoma, and 1 with multiple myeloma) were included in this study, after informed consent. Patients were prepared for transplantation using antithymocyte horse immunoglobulin (Merieaux, Paris, France) and procarbazine, followed by hyperfractionated total body irradiation and cycloph~sphamide.'~ The marrow donors were HLA-identical, mixed lymphocyte culture-compatible adult individuals (age greater than 20 years). Control subjects in this study were either marrow donors or normal individuals age-matched to the donors.
To prevent graft-versus-host disease (GVHD), the marrow transplants were depleted of T cells by sequential soybean agglutination and sheep red blood cell rosetting, according to a procedure described by Reisner et a1."
Engraftment was documented by blood group change or by cytogenetic analysis of sex marker conversion, or disappearance of Ph chromosome. Post-BMT patients selected for this study were all successfully engrafted. No graft failure was observed in the subsequent follow-up of these patients.
Patients and controls.
Marrow graft preparation.
Posttransplant follow-up.
Marrow graft recipients received no immunosuppressive therapy for GVHD prophylaxis in the posttransplant period. Only 1 of the 20 patients developed grade I acute GVHD, while none had chronic GVHD.
Mononuclear cells were isolated by FicollHypaque (Pharmacia Fine Chemicals, Piscataway, NJ) density gradient centrifugation, and partially depleted of monocytes by adherence to plastic dishes. The CD4+ and CD8 + cell subsets were enumerated and analyzed for co-expression of CD57 and C D l l b antigens by two-color immunofluorescence. Fluorescein-conjugated Leu3 (anti-CD4) or Leu2 (anti-CD8) mouse monoclonal antibodies were used in combination with unconjugated Leu7 (anti-CD57) or Leu15 (anti-CDl lb) (Becton-Dickinson, Mountain View, CA) developed with rhodamine-conjugated goat anti-mouse IgM or IgG2a antibodies, respectively (Southern Biotechnology Associates, Birmingham, AL). Wet preparations of viable cells were examined by fluorescence microscopy. Co-expression of two markers on the same cell was evaluated by scoring at least 200 cells positive for one marker and determining the percentage of cells also expressing the other marker.
Clonal cultures (see below) were analyzed for their CD3+, CD4+, CD8+, CD56+, and CD16+ phenotypes by indirect immunofluorescence. Leu4 (anti-CD3), Leu 19 (anti-CD56) and Leulla (anti-CD16) monoclonal antibodies were purchased from Becton Dickinson (Mountain View, CA); CK.79 (anti-CD4) was obtained in our laboratories, as previously described:' and the B9.4 (anti-CD8) monoclonal antibody was kindly donated by Dr B. Malissen (INSERM, Marseille-Luminy, France). Fluoresceinconjugated goat anti-mouse antibodies (Southern Biotechnology Assoc) were used as secondary reagents. Analyses of the expression of CD57 and CDI l b antigens were not performed in clonal cultures because our previous studies at the clonal level have shown that both antigens may be lost over a relatively short culture period. 22 A preliminary survey of 20 BMT recipients revealed that co-expression of CD57 and C D l l b antigens on circulating CD4+ and CD8+ cells ranged from 40% to 85% on CD4+ cells and from 70% to 100% on CD8+ cells (see also reference 16). This is in contrast to co-expression of CD57/CDllb on T cells from normal subjects, which is 4% on CD4+ cells and 20% to 40% on CD8+ cells. Six samples (from six individual patients) representative of the observed range of NK-antigen expression were selected for cloning experiments and subsequent functional analyses of the clonal progenies. Mononuclear cells forming rosettes with sheep red blood cells (SRBC) were purified by Ficoll-Hypaque density gradient centrifugation, followed by 0.83% ammonium chloride osmotic lysis of SRBC. E-rosette forming cells were plated under limiting dilution and activated with phytohemagglutinin (PHA) (Difco Laboratories, Detroit, MI) for 24 hours before addition of IL-2. This system allows clonal expansion of up to 100% of the peripheral blood T cells." Cells were plated (from 1 to 0.25 cells per well for control cultures and from 8 to 0.5 cells per well for BMT recipients' cultures) in groups of 48 microcultures in U-bottom microwells containing lo5 irradiated (50 Gy) spleen feeder cells in RPMI 1640 medium with 10% heat-inactivated fetal calf serum (FCS) and 0.5% PHA. Recombinant IL-2 (generously provided by the GLAXO Institute for Molecular Biology SA., Geneva, Switzerland) was added at a final concentration of 25 U/mL after 24 hours. Plates were incubated at 37OC in a humidified atmosphere with 5% CO,. Microcultures were supplemented on day 7 with IO5 irradiated feeder cells and 1L-2. IL-2 was further added on day 14. Control wells contained irradiated feeder cells, PHA and IL-2 without addition of responder cells. After 14 to 18 days of culture, each microwell was assessed microscopically for cell growth. Immunofluorescence analysis of 50 arbitrarily selected clones revealed that they were all CD3 + . Frequencies of proliferating cells were then calcuImmunofluorescence.
T-cell cloning.
lated by the x2 method from the Poisson distribution relationship between the number of E + cells plated per culture and the logarithm of the percentage of non-proliferating cultures.23 In the present experiments, cloning efficiency was -50% for control cultures and -10% for patients' cultures. According to the Poisson formulae, if the cloning efficiency is loo%, positive cultures growing from 0.25 (or less) T cells plated per well are highly likely to be clonal. Therefore, growing microcultures were considered clonal when they were derived from 0.5 (or less) T cells plated per well in the case of control cultures and 2 (or less) T cells plated per well in the case of patients' cultures. Only these cultures were used for functional and phenotypic analyses and are referred to as "clones" throughout this article. In addition, those exceptional cultures exhibiting mixed CD4+/CD8 + cell populations were excluded from the analysis.
The cytolytic activity of the clones was detected in an LDCC assay as described elsewhere." This assay allows detection of all cytotoxic cells, irrespective of their spe~ificities.'~ Briefly, clonal microcultures were counted and the cell counts were adjusted at 1 x 106/mL. Fifty microliter aliquots (containing 5 x lo4 cells) of each growing microculture were incubated in V-bottomed wells of microtiter trays with 5 x lo' [SICr]-labeled P815 cells with 1% (vol/vol) PHA. Plates were centrifuged at 100 g for 2 minutes and were incubated for 4 hours at 37OC. Target cell lysis was determined by counting the radioactivity of 0.1 mL supernatants, and the specific lysis was calculated acccording to the formula:
% Specific lysis
Assays for the cytolytic activities.
Experimental release -Spontaneous release
Maximum release -Spontaneous release Assessment of LAK function of the clones was performed using [5'Cr]-labeled fresh melanoma cells as target cells in the ["Crlrelease assay described above.
Assay for ZL-2 production. Clonal microcultures were washed several times and were resuspended at a cell concentration of 1 x 106/mL in 200 pL culture medium containing 1% (vol/vol) PHA. Supernatants were removed after 24 hours for determination of IL-2 activity.
As an indicator system we used the IL-24ependent mouse CTLL cell line.25 Clonal supernatants were added to 5 x lo' indicator cells at a final concentration of 25%. IL-2 activity was assessed by ('H)-thymidine uptake of CTLL cells after a 6-hour pulse at the end of a 24-hour culture period.
Calculation of the IL-2 produced by T-cell clones was based on a standard source of recombinant IL-2 that contained a known amount of international standard units.
--

RESULTS
Cloning of T cells from BMT recipients. Circulating CD4+ and CD8 + T cells from 20 long-term (greater than 5 months) BMT recipients were analyzed by two-color immunofluorescence for co-expression of the NK-related antigens, CD57 and CDllb. Six samples representative of the observed range of NK-antigen expression on CD4+ and CD8 + cells were selected for cloning under limiting dilution conditions, and for the determination of cytolytic function and IL-2 production at the clonal level. As shown in Table 1 freshly isolated T cells from these samples co-expressed CD57 and CD11 b in very high, although variable, proportions; ie, 40% to 87% for CD4+ cells and 70% to 98% for CD8+ cells. The purpose of the subsequent experiments was to determine the effects of such phenotypic imbalances on the cytolytic potential of either the CD4+ or CD8+ subset. To this end, mononuclear cells were plated under limiting dilution conditions and activated with PHA for 24 hours before addition of IL-2. Frequencies of proliferating T cells were then calculated. The frequency of post-grafting T cells undergoing clonal expansion in this system was lower than that of control T cells (1 in 10 versus 1 in 2, as calculated by the Poisson formulae). A total of 209 clones from six BMT recipients and 62 clones from two control subjects were examined (see "Materials and Methods" for selection procedure and definition of clonality). Immunofluorescence analyses performed on separate aliquots of each growing microculture (between days 18 and 21) demonstrated that 29% of the BMT recipient-derived clones were CD4+ and 7 1% were CD8 + .
Of the 62 clonal clones examined, 56.5% were CD4+ and 43.5% were CD8 +. This distribution closely reflected the CD4/CD8 ratios detected in the original peripheral blood lymphocyte (PBL) preparations used for the cloning experiments; ie, CD4:CD8 = 1.4 to 1.2 in normal control subjects and CD4:CD8 = 0.5 to 0.3 in BMT recipients. This indicates that the relatively low cloning efficiency of BMT recipients' T cells, as opposed to that of control cells, was not a consequence of a selective inability of a given T-cell subset to give rise to clonal progenies in our system. This is also suggested by the identical cloning efficiency of CD8 + cells from the one sample in which the virtual totality of CD8 + cells co-expressed CD57 and CD1 l b compared with that of other BMT recipient-derived CD4+ or CD8+ cell populations not co-expressing NK-related antigens a t the same rate (see "Discussion").
One aliquot (50 pL) of each clonal microculture ( 5 x IO4 cells) was removed on day 18 of culture to test the cytolytic activity in an LDCC. As shown in Table 2 , the cytolytic potential of BMT recipient-derived clones was largely a property of CD8 +
LDCC of BMT recipient-derived T-cell clones.
clonal cultures, whereas approximately 1/3 of the CD4+ clones exhibited cytolytic activity. Ninety-six percent of the CD8+ clones derived from either control CD8+ cells (therefore largely NK antigen-negative) or patients' CD8 + cells (predominantly CD57+/CD1 l b + ) exhibited a marked cytolytic activity in the LDCC assay. LAK function of BMT recipient-derived T-cell clones. Of BMT recipient-derived clones, 87 of 209, and 45 of 62 control clones, yielded enough cells to allow further evaluation of their LAK activity. These clones were tested against ["Crl-labeled fresh melanoma cells.
In Fig 1 the LAK function of BMT recipient-derived clones (abscissa) is compared with the LDCC activity (ordinate). Interestingly, as many as 28% of post-BMT cytolytic clones also exhibited LAK activity as opposed to the exceptional occurrence of clones with this function among those generated from normal donors (Fig 1 and Table 2 ).
In order to evaluate their ability to produce IL-2, clonal microcultures (containing 4 x lo5 cells) were stimulated with PHA for 24 hours. The culture supernatants were then harvested and tested for IL-2 production. Of control CD4+ and CD8+ clones, 63% and 41% produced detectable amounts of IL-2. In contrast, 15%
and 7% of BMT recipient-derived CD4+ and CD8 + clones, respectively, produced IL-2 (Fig 2) . These results indicate that clonable T cells in the late reconstitution phase after BMT contain fewer cells than normal that are capable of giving rise to IL-2 producing clones.
ZL-2 production after BMT.
DISCUSSION
This study was aimed at the definition of cytolytic functions of clonable T cells from T-cell-depleted BMT recipients in a high efficiency cloning system. A lower cloning efficiency was observed in BMT recipients as compared with normal controls. Phenotypic analyses of the clones closely reflected the inverted CD4:CD8 ratios detected after BMT. In contrast to control clones, the proportions of IL-2-producing clones were low, irrespective of their CD4+ or CD8 + phenotypes. On the other hand, virtually 100% of the CD8 + clones were cytolytic when tested in an LDCC assay.
Similar analyses were performed previously by Daley et al, who have shown an overall reduction of proliferating T-cell 2) . Tested for IL-2 production were 153 clones derived from 8MT recipients and 6 2 control clones. The lower number of clones tested for LAK function and IL-2 production is due to availability of cell numbers suitable for these functional studies. In contrast, 15% and 7% of BMT recipient-derived CD4+ (0) and CD8+ (e) clones, respectively, produced IL-2 ( P <.05).
precursors with either cytolytic or IL-2 producing ability, which, however, was more pronounced in T-cell-depleted as opposed to unmanipulated BMT during the first 180 postgrafting days.26 In addition, defective production of IL-2 has not been observed at all when T-cell clones from non-Tdepleted BMT patients were analyzed at an even earlier post-BMT phase (less than 3 months)." GVHD occurring in a large proportion of these patients, together with faster T-cell recovery, may be responsible for these findings. However, also in T-depleted BMT recipients, bulk culture studies have shown spontaneous IL-2 production in the very early post-grafting phase (weeks 3 to 7).14 In accordance with our present data, in T-depleted, as well as in conventional BMT, the ability to produce IL-2 after mitogenic stimulation remains depressed for up to 1 year after transplantation.13.14 The major goal of our study was that of evaluating, at the clonal level, the relevence of T-cell-mediated LAK activity in long-term BMT recipients. Cell-mediated cytotoxicity in the setting of bone marrow transplantation for hematologic malignancy may be important for the control of residual leukemic cells that survive the pre-transplant conditioning therapy and for leukemia relapse. Among nonspecific cytotoxic cells, a major role is played by CD3 -granular lymphocytes, which are capable of mediating LAK functions upon in vitro incubation with IL-2." A wave of CD3-cells mediating NK and LAK functions can be identified during the first post-grafting weeks: ' and CD3 -clones with anti-leukemia activity have been generated from BMT patients.6 However, in normal subjects, it has been shown that LAK cells may also be generated from CD3 + T-cell precursors predominantly with a CDS+/CD57+/CDI 1b-t phenotype.'8 Cells with this phenotype are increased in BMT recipients shortly after the wave of CD3 -cytotoxic cells, and they persist at an elevated For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
